📜 iter-4360dd15-0073.log
18144 bytes
# Iter-0073 mission=4360dd15
# goal: 找到让人类长生不老的方法
# time: 2026-04-26T01:51:51
# focus_node: n176 :: 定义顺序联合证据缺口的判定语句
========== TRANSCRIPT ==========
→ call task_view({"max_depth":6})
【tool:task_view】
{"ok": true, "tree": "GOAL: 找到让人类长生不老的方法\n· [✓ done ] root: 找到让人类长生不老的方法\n├─ [✓ done ] n1: 建立 marker 锚定后的局部交换判定框架 ← 已完成 marker 锚定后的局部交换判定框架：固定 μ 锚点、排除触及 μ 的交换、用 greedy witness span 压缩候选窗口，并在触及 wit\n│ ├─ [✓ done ] n5: 规范化 witness：固定 μ 锚点并限制一次交换的位置 ← 完成 witness 规范化：确认固定 μ 锚点时必须排除触碰 μ 的交换，并用 greedy witness span 将允许交换压缩到局部窗口内；小规模穷举\n│ │ ├─ [✓ done ] n9: 证伪一次交换跨越 μ 的规范化可能性 ← 用穷举验证并归纳出结构性事实：任何触及唯一 marker μ 的相邻交换都会使 μ 的位置改变 1，因此在固定 μ 位置的 witness 规范化里，不存在“跨\n│ │ ├─ [✓ done ] n10: 把单侧交换位置压缩为可判定窗口 ← 证明并穷举验证：对左块 greedy witness 的最左/最右嵌入位置 p1..pk，窗口外相邻交换不会改变最大前缀消耗 k，因此允许交换位置可压缩为 [p\n│ │ └─ [✓ done ] n11: 沉淀 witness 规范形模板 ← 沉淀出 witness 规范形模板：固定 μ 锚点、排除触及 μ 的交换、以 greedy witness span 限定局部窗口，并用左块最大前缀消耗 k 作\n│ ├─ [✓ done ] n6: 建立单侧切分判定接口：把可行性压成存在切分点 k ← 把固定 μ 锚点后的可行性压成了单侧切分接口：左块只通过最大前缀消耗长度 k 传递，且 k 由 X 决定、与 Y 无关。\n│ ├─ [✓ done ] n7: 刻画交换不依赖右侧的充分条件 ← 验证了一个可复用充分条件：若一次相邻交换不改变对任意 S 的左块最大前缀消耗 k，则对所有右侧 Y 的可行性判定保持不变；并用穷举检查了 small-case \n│ ├─ [✓ done ] n8: 沉淀可复用的验证模板与失败边界 ← 找到验证模板的失败边界：任意 witness span 不够，必须用 greedy witness span；给出反例 X=abb, S=ba，窗口外交换仍可改\n│ ├─ [✓ done ] n12: 探索两次相邻交换下 greedy witness span 的局部性边界 ← 在二元字母表、长度 n<=8 的穷举中，未找到“两个相邻交换都发生在原始 greedy witness span 之外却改变 k”的反例；这给出了多交换局部性边\n│ ├─ [✓ done ] n13: 把 marker 锚定后的局部交换判定落实为可执行的 O(n)~O(n log n) 检查流程 ← 完成了一个可执行的局部交换检查流程：先算 k，再用 greedy witness span 的局部闭包限制候选交换；对二元字母表、|X|<=8、|S|<=8 的\n│ ├─ [✓ done ] n14: 证伪 greedy witne
→ call search_memory({"limit":8,"mission_only":false,"query":"OSK safety go/no-go stop condition partial reprogramming senolytic"})
【tool:search_memory】
{"ok": true, "results": [{"title": "部分重编程 go/no-go 判据与安全边界", "tags": "fact principle method lesson", "mission": "", "modified": "20260425020626000", "preview": "!! 部分重编程 go/no-go 判据与安全边界 ''核心原则'': 对以 OSK/部分重编程为代表的 rejuvenation 干预，''不能只看“变年轻”''；必须把''疗效''与''身份安全''分开判定。 !! Go 判据（至少同时满足） # ''表观年龄回退'': 目标组织的 DNA 甲基化年龄/age acceleration 下降，优先使用[[组织特异]]时钟，辅以 pan-tissue / mammalian clock 作为交叉验证。 # ''功能改善'': 组织/器官的衰弱、再生、运动/认知/生理输出等至少一类功能终点改善。 # ''组织结构改善'': 纤维化、炎症、病理损伤或器官结构指标不恶化，最好同步改善。 # ''身份保持'': 细胞类型标志、谱系约束与组织特异转录/染色质特征未出现明显丢失。 !! No-go / stop 规则 # 出现明显''去分化''"}, {"title": "senolytic 预处理与 OSK 增效证据未检出", "tags": "fact lesson evidence-chain method 4360dd15", "mission": "", "modified": "20260425031913000", "preview": "!! senolytic 预处理对 OSK/partial reprogramming 的‘增效/保安全’原始证据目前未检出 ''结论'': 以 PubMed + 网页检索覆盖 senolytic（ABT-263/navitoclax/quercetin）与 OSK/partial reprogramming 的组合后，当前没有找到把 ''senolytic 预处理'' 明确连接到 ''OSK/partial reprogramming''，并以重编程效率、安全边界或去分化风险为终点的原始实验。 ''邻近证据'': * ABT-263 pretreatment 可改善 OA 患者来源 synovial MSC 的克隆形成、分化能力与 senescence 指标，但这是细胞治疗/MSC 修复场景，不是 OSK。 * ABT-263 的 senolytic 响应与 parental cell"}, {"title": "骨相关系统中的 senolytic→OSK 顺序实验仍未检出", "tags": "fact lesson evidence-gap senolytic OSK bone", "mission": "", "modified": "20260425171453000", "preview": "!! 骨相关系统中的 senolytic→OSK 顺序实验仍未检出 ''结论'': 在 PubMed 中对骨相关系统做定向检索（bone / skeletal / osteoblast / osteogenesis / MSC / fracture / osteotomy），并联合 senolytic（navitoclax, ABT-263, dasatinib/quercetin, D+Q）与 OSK/partial reprog
→ call pubmed_search({"limit":10,"query":"partial reprogramming safety stop condition dedifferentiation teratoma OSK navitoclax senolytic toxicity thrombocytopenia"})
【tool:pubmed_search】
{"ok": true, "query": "partial reprogramming safety stop condition dedifferentiation teratoma OSK navitoclax senolytic toxicity thrombocytopenia", "results": []}
→ call pubmed_search({"limit":8,"query":"OSK partial reprogramming safety dedifferentiation cancer teratoma mouse"})
→ call pubmed_search({"limit":8,"query":"senolytic navitoclax toxicity thrombocytopenia mouse safety"})
→ call web_search({"limit":8,"query":"partial reprogramming safety dedifferentiation teratoma OSK review"})
→ call web_search({"limit":8,"query":"navitoclax thrombocytopenia senolytic safety review"})
【tool:pubmed_search】
{"ok": true, "query": "OSK partial reprogramming safety dedifferentiation cancer teratoma mouse", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "senolytic navitoclax toxicity thrombocytopenia mouse safety", "results": []}
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
【tool:web_search】
{"ok": false, "error": "[Errno 101] Network is unreachable"}
→ call pubmed_search({"limit":10,"query":"partial reprogramming OSK safety mouse dedifferentiation"})
→ call pubmed_search({"limit":10,"query":"navitoclax thrombocytopenia study"})
→ call pubmed_search({"limit":10,"query":"ABT-263 thrombocytopenia senolytic mouse"})
→ call pubmed_search({"limit":10,"query":"Yamanaka factor partial reprogramming safety in vivo"})
【tool:pubmed_search】
{"ok": true, "query": "partial reprogramming OSK safety mouse dedifferentiation", "results": []}
【tool:pubmed_search】
{"ok": true, "query": "navitoclax thrombocytopenia study", "results": [{"pmid": "41901278", "title": "The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke.", "source": "Pharmaceuticals (Basel)", "pubdate": "2026 Mar 6", "authors": ["Falahatgaroshibi D", "Baixauli-Martín J", "Burguete MC", "López-Morales MA", "Aliena-Valero A", "Peris JE", "Salom JB"], "url": "https://pubmed.ncbi.nlm.nih.gov/41901278/"}, {"pmid": "41807411", "title": "Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming.", "source": "NPJ Aging", "pubdate": "2026 Mar 10", "authors": ["Zhang W", "Song S", "Zhang Y", "Pan Y", "Hu D", "Wang Y"], "url": "https://pubmed.ncbi.nlm.nih.gov/41807411/"}, {"pmid": "41784189", "title": "Evaluation of Drugs with Selective Inhibitors Targeting the Anti-Apoptotic Protein B-cell Lymphoma 2 (BCL-2) with Pro-Apoptotic and Antineoplastic Activities in Grade IV Glioblastoma.", "source": "Turk Neurosurg", "pubdate": "2026", "authors": ["Baloglu M", "Tamdogan T", "Ondul S", "Bakirtas M", "Yilmaz I"], "url": "https://pubmed.ncbi.nlm.nih.gov/41784189/"}, {"pmid": "41761659", "title": "Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis.", "source": "Ann Med", "pubdate": "2026 Dec", "authors": ["Tan S", "Li Y", "Cao Y", "Sun W", "Hui W"], "url": "https://pubmed.ncbi.nlm.nih.gov/41761659/"}, {"pmid": "41727313", "title": "Dif
【tool:pubmed_search】
{"ok": true, "query": "ABT-263 thrombocytopenia senolytic mouse", "results": [{"pmid": "41727313", "title": "Differential responses to the combination of navitoclax and venetoclax with doxorubicin in murine models of triple negative breast cancer.", "source": "Front Cell Dev Biol", "pubdate": "2026", "authors": ["As Sobeai HM", "Alanazi AM", "Alotaibi F", "Alhoshani A", "Alhazzani K", "Almutairi MM", "Almudimeegh S", "Al-Ramadi BK"], "url": "https://pubmed.ncbi.nlm.nih.gov/41727313/"}, {"pmid": "38534371", "title": "PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer.", "source": "Cells", "pubdate": "2024 Mar 17", "authors": ["Khan S", "Cao L", "Wiegand J", "Zhang P", "Zajac-Kaye M", "Kaye FJ", "Zheng G", "Zhou D"], "url": "https://pubmed.ncbi.nlm.nih.gov/38534371/"}, {"pmid": "38464204", "title": "PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.", "source": "bioRxiv", "pubdate": "2024 Mar 1", "authors": ["Khan S", "Cao L", "Wiegand J", "Zhang P", "Zajac-Kaye M", "Kaye FJ", "Zheng G", "Zhou D"], "url": "https://pubmed.ncbi.nlm.nih.gov/38464204/"}, {"pmid": "32677976", "title": "DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.", "source": "J Hematol Oncol", "pubdate": "2020 Jul 16", "authors": ["He Y", "Koch R", "Budamagunta V", "Zhang P", "Zhang X", "Khan S", "Thummuri D", "Ortiz YT"], "url
【tool:pubmed_search】
{"ok": true, "query": "Yamanaka factor partial reprogramming safety in vivo", "results": [{"pmid": "42013916", "title": "OSK-mediated partial reprogramming induces cardiomyocyte dedifferentiation, overcomes cytokinesis barriers, and promotes post-MI endogenous cardiac regeneration.", "source": "J Mol Cell Cardiol", "pubdate": "2026 Apr 19", "authors": ["Yan Y", "Huang Y", "Cao C", "Li D", "Che Y", "Wang Q", "Liu Y", "Zhang Q"], "url": "https://pubmed.ncbi.nlm.nih.gov/42013916/"}]}
→ call read_note({"title":"部分重编程 go/no-go 判据与安全边界"})
【tool:read_note】
{"ok": true, "title": "部分重编程 go/no-go 判据与安全边界", "tags": "fact principle method lesson", "text": "!! 部分重编程 go/no-go 判据与安全边界\n\n''核心原则'': 对以 OSK/部分重编程为代表的 rejuvenation 干预，''不能只看“变年轻”''；必须把''疗效''与''身份安全''分开判定。\n\n!! Go 判据（至少同时满足）\n# ''表观年龄回退'': 目标组织的 DNA 甲基化年龄/age acceleration 下降，优先使用[[组织特异]]时钟，辅以 pan-tissue / mammalian clock 作为交叉验证。\n# ''功能改善'': 组织/器官的衰弱、再生、运动/认知/生理输出等至少一类功能终点改善。\n# ''组织结构改善'': 纤维化、炎症、病理损伤或器官结构指标不恶化，最好同步改善。\n# ''身份保持'': 细胞类型标志、谱系约束与组织特异转录/染色质特征未出现明显丢失。\n\n!! No-go / stop 规则\n# 出现明显''去分化''、''谱系漂移''、异常增殖或肿瘤样信号。\n# 关键组织标志和功能标志持续下降，提示身份破坏大于年轻化收益。\n# 表观年龄回退仅是短暂波动，而功能/结构/身份任一面板出现恶化。\n# 剂量或脉冲方案引发持续性炎症、纤维化加重、组织失稳或不可逆损伤。\n\n!! 安全边界设计\n# 默认采用''短脉冲、循环式、可诱导、局部递送''，避免长期持续表达。\n# 先设''身份稳定性''为硬门槛，再谈年龄回拨幅度。\n# 将安全读出与疗效读出并列，而不是作为事后补充。\n\n!! 可复用判定模板\n''Go'' = 年龄回退 AND 功能改善 AND 组织完整性改善/不恶化 AND 身份稳定\n\n''No-go'' = 任一出现：去分化、异常增殖、病理恶化、持续炎症、不可逆组织损伤\n\n''备注'': 这一框架与文献综述中反复强调的结论一致：partial reprogramming 的关键不是单纯降低年龄标记，而是''在保留细胞身份前提下''实现可验证的 rejuvenation。"}
→ call search_memory({"limit":5,"mission_only":false,"query":"senolytic platelet toxicity safety boundary ABT-263 navitoclax"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Topical ABT-263 in aged mouse skin: original study and readouts", "tags": "fact method lesson 4360dd15", "mission": "", "modified": "20260425025523000", "preview": "!! Topical ABT-263 in aged mouse skin: original study and executable parameters ''Original study'': [[PMID 39630941]] / PMCID PMC11810067, ''Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing'' (Aging, 2024). !! Executable parameter table |~ Dimension |~ ABT-263 skin study | | Organism | aged mice | | Age | 24-month-old for treatment cohort; 2-month-old y"}, {"title": "senolytic 预处理与 OSK 增效证据未检出", "tags": "fact lesson evidence-chain method 4360dd15", "mission": "", "modified": "20260425031913000", "preview": "!! senolytic 预处理对 OSK/partial reprogramming 的‘增效/保安全’原始证据目前未检出 ''结论'': 以 PubMed + 网页检索覆盖 senolytic（ABT-263/navitoclax/quercetin）与 OSK/partial reprogramming 的组合后，当前没有找到把 ''senolytic 预处理'' 明确连接到 ''OSK/partial reprogramming''，并以重编程效率、安全边界或去分化风险为终点的原始实验。 ''邻近证据'': * ABT-263 pretreatment 可改善 OA 患者来源 synovial MSC 的克隆形成、分化能力与 senescence 指标，但这是细胞治疗/MSC 修复场景，不是 OSK。 * ABT-263 的 senolytic 响应与 parental cell"}, {"title": "皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到", "tags": "lesson fact method 4360dd15", "mission": "", "modified": "20260425022429000", "preview": "!! 皮肤中 OSK vs ABT-263 的原始 head-to-head 目前未检到 ''检索结论'': 以 skin / dorsal skin / skin aging / OSK / partial reprogramming / Yamanaka factors / ABT-263 / navitoclax / senolytic / head-to-he
→ call write_note({"tags":["fact","principle","method","lesson","[[senolytic→OSK 顺序联合的原始证据边界]]","[[部分重编程 go/no-go 判据与安全边界]]"],"text":"!! 部分重编程 go/no-go 判据与安全边界\n\n''核心原则'': 对以 [[OSK]] / 部分重编程为代表的 rejuvenation 干预，''不能只看“变年轻”''；必须把''疗效''与''身份安全''分开判定。\n\n!! Go 判据（至少同时满足）\n# ''表观年龄回退'': 目标组织的 DNA 甲基化年龄/age acceleration 下降，优先使用[[组织特异]]时钟，辅以 pan-tissue / mammalian clock 作为交叉验证。\n# ''功能改善'': 组织/器官的衰弱、再生、运动/认知/生理输出等至少一类功能)
【tool:write_note】
{"ok": true, "path": "/root/Sisyphus/wiki/tiddlers/部分重编程_go_no-go_判据与安全边界.tid", "title": "部分重编程 go/no-go 判据与安全边界"}
→ call task_done({"id":"n175","result":"把顺序联合的最小安全边界收束为两类停药条件：OSK 侧以去分化/异常增殖/组织失稳为 no-go，senolytic 侧以血小板下降等已知系统毒性为独立停药边界；并将其写入通用 go/no-go 模板。"})
【tool:task_done】
{"ok": true, "id": "n175", "status": "done", "next_focus": "n176"}
【assistant】
已完成本轮焦点：把 senolytic→OSK 的最小设计补上了“安全边界与停药条件”。
本轮新证据：
- PubMed 对 “partial reprogramming OSK safety dedifferentiation cancer teratoma mouse” 未检出直接条目；
- 对 “navitoclax thrombocytopenia senolytic safety” 检到与 BCL-xL / navitoclax 毒性相关的文献线索，支持把血小板下降类血液学毒性单列为停药边界；
- 已把这些边界写入记忆：`部分重编程 go/no-go 判据与安全边界`。
任务树更新：
- `n175` 已 done
- 下一焦点自动转到 `n176`
<NEXT_FOCUS>定义顺序联合证据缺口的判定语句</NEXT_FOCUS>
========== REFLECTION ==========
{
"progress": "把 senolytic→OSK 顺序联合的最小设计补齐到可执行的安全门槛：OSK 侧用去分化/异常增殖/组织失稳作硬停药边界，senolytic 侧把血小板等已知系统毒性单独列为停药条件。",
"failure": "没有检到可直接支持“senolytic 预处理能提升 OSK 安全性/效率”的原始顺序联合证据，且网络检索失败使灰文献入口受限。",
"empirical_actions": "调用了 task_view、search_memory、read_note、write_note，并进行了多轮 pubmed_search；web_search 受网络不可达影响失败，PubMed 仅返回少量邻近结果（如 OSK 心肌细胞去分化/再生、navitoclax 相关论文）而未找到直接顺序联合证据。",
"lesson": {
"worthy": false,
"title": "",
"extends_existing": "",
"tags": [],
"text": ""
},
"next_focus": "把 senolytic→OSK 的最小证据门槛进一步收缩到“同一组织、同一终点、同一时间窗”的头对头/顺序对照原始实验。"
}